Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors
TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01
IMAG1NE…
Berlin, Germany and Stockholm, Sweden, October 20, 2022:
FyoniBio, a CDO expert specialized in tailored cell line development and Strike Pharma, whose proprietary
Adaptable Drug Affinity Conjugate (ADAC) technology enables development of …
The term “Long COVID” first emerged in the social media. Numerous affected individuals have reported in the social media about their various, long-lasting health limitations after SARS-CoV-2 infection. In the Berlin-Brandenburg metropolitan region,…
pharmtrace, a German, Berlin based provider of Independent expertise for nuclear medicine, diagnostics, and drug development clinical trials has established a representative office in Philadelphia. pharmtrace is currently enjoying increasing…
NUVISAN’s integrated drug discovery expertise leveraged in a grant from the Bill & Melinda Gates Foundation
To prevent diseases from occurring in the first place, it is important to identify those individuals who are at particularly high risk as early as possible. Yet current screening methods are often costly and focus only on one disease at a time.…
BRCA1/2-mutated tumor cells often survive treatment, whether it’s chemo- or radiotherapy, because they can repair therapy-induced DNA damage. A team led by Claus Scheidereit of the Max Delbrück Center has now reported in The EMBO Journal how blocking…
If a secretion in the lungs’ alveoli is not cleared regularly, breathing difficulties can develop. In a study published in Science Immunology, a team led by Alexander Mildner and Achim Leutz has now explained the pivotal role of the transcription…
An international research consortium led by the Berlin Institute of Health at Charité (BIH) has secured funding of €7.5 million through the EU’s current Horizon Europe program. The goal of the participating scientific and clinical specialists is to…
